{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"COCH","limit":50},"count":50,"signals":[{"ticker":"COCH","company":"Envoy Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":100,"match_count":32,"context":"; 2.To ratify the appointment of EisnerAmper LLP as Envoy Medicals independent registered public accounting firm for the year ending December31, 2026; 3.To approve, on an advisory basis, the Companys named executive officer (NEO) compensation; 4.To approve an amendment to the Envoy Medical, Inc. 2023 Equity Incentive Plan; 5.To approve an amendment to the Envoy Medical, Inc. 2023 Employee Stock Purchase Plan; 6.To appro","filed_date":"2026-04-02","accession":"0001213900-26-039310","full_text":"https://origin.rootz.global/static/filing/0001213900-26-039310.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"COCH","company":"Envoy Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"el clinical trial to evaluate the safety and efficacy of the Acclaim CI. The pivotal clinical study protocol currently requires 56 total patients enrolled and followed for 12 months. We completed enrollment of all 56 patients on March 10, 2025. The pivotal clinical study protocol has primary efficacy and safety endpoints, many secondary endpoints and few exploratory endpoints. The primary efficacy en","filed_date":"2026-03-23","accession":"0001213900-26-032683","full_text":"https://origin.rootz.global/static/filing/0001213900-26-032683.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"COCH","company":"Envoy Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":42,"context":"ctors, including those described in this *Risk Factors* section, many of which are beyond our control and may not be related to our operating performance. Any of the factors listed below could have a material adverse effect on investment in our Class A Common Stock, and our Class A Common Stock may trade at prices significantly below the price paid for them. In such circumstances, the trading prices of our Class A Commo","filed_date":"2026-03-23","accession":"0001213900-26-032683","full_text":"https://origin.rootz.global/static/filing/0001213900-26-032683.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"COCH","company":"Envoy Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"laim CI was granted by the FDA in October of 2024. Seven investigational sites were selected prior to the end of 2024. The IDE was approved as a staged clinical trial. The first stage allowed for enrollment of 10 study participants prior to the Company having to formally request FDA approval to expand enrollment to the full subject cohort of 56 patients. The Company collected and submitted preliminar","filed_date":"2025-12-18","accession":"0001213900-25-123367","full_text":"https://origin.rootz.global/static/filing/0001213900-25-123367.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"COCH","company":"Envoy Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":37,"context":"ctors, including those described in this *Risk Factors* section, many of which are beyond our control and may not be related to our operating performance. Any of the factors listed below could have a material adverse effect on investment in our Common Stock, and our Common Stock may trade at prices significantly below the price paid for them. In such circumstances, the trading prices of our Common Stock may not recover","filed_date":"2025-12-18","accession":"0001213900-25-123367","full_text":"https://origin.rootz.global/static/filing/0001213900-25-123367.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"COCH","company":"Envoy Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":100,"match_count":17,"context":"y and potential other individuals and to establish an appropriate relationship between executive compensation and the creation of stockholder value. For the years ended December31, 2024 and 2023, our named executive officers were Brent T.Lucas, our Chief Executive Officer, and David R.Wells, our Chief Financial Officer. **** **Summary Compensation Table** The following table sets forth information concerning the compens","filed_date":"2025-12-18","accession":"0001213900-25-123367","full_text":"https://origin.rootz.global/static/filing/0001213900-25-123367.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"COCH","company":"Envoy Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":100,"match_count":14,"context":"pant holding an Award that constitutes deferred compensation under Section 409A is a specified employee for purposes of Section 409A, no distribution or payment of any amount that is due because of a separation from service (as defined in Section 409A without regard to alternative definitions thereunder) will be issued or paid before the date that is six months and one day following the date of such Participants","filed_date":"2025-06-03","accession":"0001213900-25-050758","full_text":"https://origin.rootz.global/static/filing/0001213900-25-050758.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"COCH","company":"Envoy Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":100,"match_count":46,"context":";s independent registered public accounting firm for the year ending December 31, 2025; 3.      To approve, on an advisory basis, the Company’s named executive officer (NEO) compensation; 4.      To approve an amendment to the Envoy Medical, Inc. 2023 Equity Incentive Plan; and 5.    �","filed_date":"2025-04-18","accession":"0001213900-25-033385","full_text":"https://origin.rootz.global/static/filing/0001213900-25-033385.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"COCH","company":"Envoy Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":44,"context":"ommercialization of the Acclaim CI to generate revenues. As a result, factors adversely affecting our ability to successfully commercialize, or the pricing of or demand for, this product could have a material adverse effect on our financial condition and results of operations. If we are unable to successfully commercialize or create market demand for the Acclaim CI, we will have limited ability to generate revenues. Fur","filed_date":"2025-03-31","accession":"0001013762-25-004299","full_text":"https://origin.rootz.global/static/filing/0001013762-25-004299.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"COCH","company":"Envoy Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":23,"context":"to such term in Section 3(u). Issuer Free Writing Prospectus shall mean an issuer free writing prospectus, as defined in Rule 433. Losses shall have the meaning ascribed to such term in Section 7(d). Material Adverse Effect shall have the meaning ascribed to such term in Section 3(b). Material Permits shall have the meaning ascribed to such term in Section 3(s). Net Proceeds shall have the meaning ascribed to such term","filed_date":"2025-01-21","accession":"0001213900-25-004714","full_text":"https://origin.rootz.global/static/filing/0001213900-25-004714.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"COCH","company":"Envoy Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":100,"match_count":46,"context":";s independent registered public accounting firm for the year ending December 31, 2024; 3.      To approve, on an advisory basis, the Company’s named executive officer (NEO) compensation; 4.      To recommend, on an advisory basis, the frequency of votes on named executive officer compensation; and 5.  ","filed_date":"2024-10-04","accession":"0001213900-24-085572","full_text":"https://origin.rootz.global/static/filing/0001213900-24-085572.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"COCH","company":"Envoy Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":45,"context":"ommercialization of the Acclaim CI to generate revenues. As a result, factors adversely affecting our ability to successfully commercialize, or the pricing of or demand for, this product could have a material adverse effect on our financial condition and results of operations. If we are unable to successfully commercialize or create market demand for the Acclaim CI, we will have limited ability to generate revenues. Fur","filed_date":"2024-04-01","accession":"0001213900-24-028894","full_text":"https://origin.rootz.global/static/filing/0001213900-24-028894.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"COCH","company":"Envoy Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":100,"match_count":17,"context":"he Company and potential other individuals and to establish an appropriate relationship between executive compensation and the creation of stockholder value. For the year ended December 31, 2023, our named executive officers were Brent T. Lucas, our Chief Executive Officer, and David R. Wells, our Chief Financial Officer, and for the year ended December 31, 2022, our named executive officer was Brent T. Lucas, our Chief","filed_date":"2024-04-01","accession":"0001213900-24-028894","full_text":"https://origin.rootz.global/static/filing/0001213900-24-028894.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"COCH","company":"Envoy Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":39,"context":"mplied, and whether exclusively, non-exclusively, through a license, through a covenant, or on any other basis) or to which the Company or any Company Subsidiary otherwise has a right to use. Company Material Adverse Effect means any event, circumstance, change, development, effect or occurrence (collectively Effect) that, individually or in the aggregate with all other Effects, is or would reasonably be expected to (a)","filed_date":"2023-04-18","accession":"0001104659-23-046443","full_text":"https://origin.rootz.global/static/filing/0001104659-23-046443.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"COCH","company":"Envoy Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":9,"context":"f a single or limited number of products, processes or services. | | This lack of diversification may subject us to numerous economic, competitive and regulatory risks, any or all of which may have a substantial adverse impact upon the particular industry in which we may operate subsequent to our initial business combination. Limited Ability to Evaluate the Targets Management Team Although we intend to closely scrutinize t","filed_date":"2023-04-03","accession":"0001104659-23-040842","full_text":"https://origin.rootz.global/static/filing/0001104659-23-040842.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"COCH","company":"Envoy Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":8,"context":"f a single or limited number of products, processes or services. | | This lack of diversification may subject us to numerous economic, competitive and regulatory risks, any or all of which may have a substantial adverse impact upon the particular industry in which we may operate subsequent to our initial business combination. Limited Ability to Evaluate the Targets Management Team Although we intend to closely scrutinize t","filed_date":"2022-03-31","accession":"0001104659-22-041094","full_text":"https://origin.rootz.global/static/filing/0001104659-22-041094.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"COCH","company":"Envoy Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":18,"context":"terial adverse change in the condition, financial or otherwise, or in the earnings, business affairs or business prospects of the Company, whether or not arising in the ordinary course of business (a Material Adverse Effect), (B) there have been no transactions entered into by the Company, other than those in the ordinary course of business, which are material with respect to the Company, and (C) there has been no divid","filed_date":"2021-03-04","accession":"0001104659-21-032172","full_text":"https://origin.rootz.global/static/filing/0001104659-21-032172.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"COCH","company":"Envoy Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"ai_adoption","strength":96,"match_count":12,"context":"ordance with the terms hereof and shall include the terms of particular series of Securities established as contemplated by Section 2.01. **Interest Payment Date**, when used with respect to any installment of interest on a Security of a particular series, means the date specified in such Security or in a Board Resolution or in an indenture supplemental hereto with respect to such series as the fixed","filed_date":"2024-10-03","accession":"0001213900-24-084734","full_text":"https://origin.rootz.global/static/filing/0001213900-24-084734.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"COCH","company":"Envoy Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"ai_adoption","strength":96,"match_count":12,"context":"laim CI was granted by the FDA in October of 2024. Seven investigational sites were selected prior to the end of 2024. The IDE was approved as a staged clinical trial. The first stage allowed for enrollment of 10 study participants (First Stage) prior to us having to formally request FDA approval to expand enrollment to the full subject cohort of 56 patients (Second Stage). Once the First Stage compl","filed_date":"2026-08-10","accession":"0001213900-26-086974","full_text":"https://origin.rootz.global/static/filing/0001213900-26-086974.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"COCH","company":"Envoy Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":72,"match_count":9,"context":"verance payments or separation benefits that are considered deferred compensation under Section 409A (together, the **Deferred Payments**) will be paid or otherwise provided until the Executive has a separation from service within the meaning of Section 409A. To the extent required to be exempt from or comply with Section 409A, references to the termination of the Executives employment or similar phrases used in","filed_date":"2023-10-20","accession":"0001013762-23-005437","full_text":"https://origin.rootz.global/static/filing/0001013762-23-005437.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"COCH","company":"Envoy Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":72,"match_count":9,"context":"verance payments or separation benefits that are considered deferred compensation under Section 409A (together, the **Deferred Payments**) will be paid or otherwise provided until the Executive has a separation from service within the meaning of Section 409A. To the extent required to be exempt from or comply with Section 409A, references to the termination of the Executives employment or similar phrases used in","filed_date":"2026-08-27","accession":"0001213900-26-094447","full_text":"https://origin.rootz.global/static/filing/0001213900-26-094447.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"COCH","company":"Envoy Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":68,"match_count":6,"context":"r maintain marketing clearance or approval for our new products or enhanc eme nts or modifications to existing products. The failure to maintain approvals or obtain approval or clearance could have a material adverse effect on our business. The use, misuse or off - label use of our products may result in injuries that lead to product liability suits, which could be cos tly to our business. Healthcare reform measures cou","filed_date":"2023-02-22","accession":"0001104659-23-024112","full_text":"https://origin.rootz.global/static/filing/0001104659-23-024112.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"COCH","company":"Envoy Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"ai_adoption","strength":64,"match_count":8,"context":"laim CI was granted by the FDA in October of 2024. Seven investigational sites were selected prior to the end of 2024. The IDE was approved as a staged clinical trial. The first stage allowed for enrollment of 10 study participants prior to the Company having to formally request FDA approval to expand enrollment to the full subject cohort of 56 patients. The Company collected and submitted preliminar","filed_date":"2025-11-10","accession":"0001213900-25-107902","full_text":"https://origin.rootz.global/static/filing/0001213900-25-107902.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"COCH","company":"Envoy Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":64,"match_count":8,"context":"On November 14, 2024, Envoy Medical, Inc. (the Company) held its 2024 Annual Meeting of Stockholders (the Annual Meeting). At the Annual Meeting: | 1. | The Companys stockholders (the Stockholders) elected two Class I director nominees to the Companys Board of Directors to hold office until the earlier of the 2027 annual meeting of stockholders, the election of such directors successor, or such directors death, resignation","filed_date":"2024-11-20","accession":"0001213900-24-100544","full_text":"https://origin.rootz.global/static/filing/0001213900-24-100544.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"COCH","company":"Envoy Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":63,"match_count":6,"context":"r maintain marketing clearance or approval for our new products or enhanc eme nts or modifications to existing products. The failure to maintain approvals or obtain approval or clearance could have a material adverse effect on our business. The use, misuse or off - label use of our products may result in injuries that lead to product liability suits, which could be cos tly to our business. Healthcare reform measures cou","filed_date":"2023-02-06","accession":"0001104659-23-010912","full_text":"https://origin.rootz.global/static/filing/0001104659-23-010912.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"COCH","company":"Envoy Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":61,"match_count":7,"context":"at the meeting of our board of directors or by a majority of the holders of our shares of common stock (or, prior to our initial business combination, holders of our founder shares). Our officers are appointed by the board of directors and serve at the discretion of the board of directors, rather than for specific terms of office. Our board of directors is authorized to appoint persons to the offices set forth in our amended and r","filed_date":"2022-03-31","accession":"0001104659-22-041094","full_text":"https://origin.rootz.global/static/filing/0001104659-22-041094.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"COCH","company":"Envoy Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"ai_adoption","strength":56,"match_count":7,"context":"k for its business, productivity, plans and goals for future operational improvements and capital investments; the timing and results of IRB approvals, site documents, logistics or activ ati ons, enrollments, follow - up visits, data, and clinical trials of the Acclaim CI, and the participation or any changes in participation of any subjects, institutions or healthcare professionals in such trials; t","filed_date":"2025-12-16","accession":"0001213900-25-121987","full_text":"https://origin.rootz.global/static/filing/0001213900-25-121987.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"COCH","company":"Envoy Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"ai_adoption","strength":56,"match_count":7,"context":"Battery. Revenue from extended warranty plans is recognized ratably over time and was immaterial for each of three months ended March 31, 2025 and 2024. Amounts received from a customer prior to fulfillment of the performance obligation are included as accrued expenses on the condensed consolidated balance sheets and are immaterial as of March31, 2025 and December31, 2024. The Company has elected to","filed_date":"2025-05-01","accession":"0001213900-25-038468","full_text":"https://origin.rootz.global/static/filing/0001213900-25-038468.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"COCH","company":"Envoy Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"ai_adoption","strength":56,"match_count":7,"context":"udicial challenge to the ACA without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Courts decision, President Biden issued an executive order to initiate a special enrollment period from February 15, 2021 through August 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agen","filed_date":"2025-03-31","accession":"0001013762-25-004299","full_text":"https://origin.rootz.global/static/filing/0001013762-25-004299.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"COCH","company":"Envoy Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":49,"match_count":3,"context":"may be required to reduce certain of its discretionary spending. The Company may be unable to develop new or enhanced production methods, or be unable to fund capital expenditures, which could have a material adverse effect on the Companys financial position, results of operations, cash flows, and ability to achieve its intended business objectives. These matters raise substantial doubt about the Companys ability to con","filed_date":"2025-11-10","accession":"0001213900-25-107902","full_text":"https://origin.rootz.global/static/filing/0001213900-25-107902.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"COCH","company":"Envoy Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":49,"match_count":3,"context":"may be required to reduce certain of its discretionary spending. The Company may be unable to develop new or enhanced production methods, or be unable to fund capital expenditures, which could have a material adverse effect on the Companys financial position, results of operations, cash flows, and ability to achieve its intended business objectives. These matters raise substantial doubt about the Companys ability to con","filed_date":"2025-07-31","accession":"0001213900-25-069663","full_text":"https://origin.rootz.global/static/filing/0001213900-25-069663.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"COCH","company":"Envoy Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":49,"match_count":3,"context":"may be required to reduce certain of its discretionary spending. The Company may be unable to develop new or enhanced production methods, or be unable to fund capital expenditures, which could have a material adverse effect on the Companys financial position, results of operations, cash flows, and ability to achieve its intended business objectives. These matters raise substantial doubt about the Companys ability to con","filed_date":"2025-05-01","accession":"0001213900-25-038468","full_text":"https://origin.rootz.global/static/filing/0001213900-25-038468.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"COCH","company":"Envoy Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":49,"match_count":3,"context":"may be required to reduce certain of its discretionary spending. The Company may be unable to develop new or enhanced production methods, or be unable to fund capital expenditures, which could have a material adverse effect on the Companys financial position, results of operations, cash flows, and ability to achieve its intended business objectives. The unaudited condensed consolidated financial statements have been pre","filed_date":"2026-08-10","accession":"0001213900-26-086974","full_text":"https://origin.rootz.global/static/filing/0001213900-26-086974.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"COCH","company":"Envoy Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"ai_adoption","strength":48,"match_count":6,"context":"99.1** **Envoy Medical Receives FDA Approval to Advance its Pivotal Clinical Trial to Final Stage Based on Submission of Promising Three-Month Data** ** ** **The Company expects to complete full enrollment by early 2026 and is moving its timelines up three to six months, cutting its anticipated capital need by $10-$15 million** ** ** **White Bear Lake, MN October 7, 2025** Envoy Medical, Inc. (NASDA","filed_date":"2025-10-07","accession":"0001213900-25-096845","full_text":"https://origin.rootz.global/static/filing/0001213900-25-096845.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"COCH","company":"Envoy Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"ai_adoption","strength":48,"match_count":6,"context":"(IRB) approvals and been successfully activated. The two remaining sites are waiting for IRB approval and activation. The IDE was approved as a staged clinical trial with the first stage allowing enrollment of 10 study participants. Envoy Medical may request expansion into the second stage once it has discussed initial three to six month data on the 10 study participants with the FDA. If allowed by t","filed_date":"2025-07-31","accession":"0001213900-25-069663","full_text":"https://origin.rootz.global/static/filing/0001213900-25-069663.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"COCH","company":"Envoy Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"ai_adoption","strength":48,"match_count":6,"context":"udicial challenge to the ACA without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Courts decision, President Biden issued an executive order to initiate a special enrollment period from February 15, 2021 through August 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agen","filed_date":"2024-04-01","accession":"0001213900-24-028894","full_text":"https://origin.rootz.global/static/filing/0001213900-24-028894.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"COCH","company":"Envoy Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":48,"match_count":6,"context":"at the meeting of our board of directors or by a majority of the holders of our shares of common stock (or, prior to our initial business combination, holders of our founder shares). Our officers are appointed by the board of directors and serve at the discretion of the board of directors, rather than for specific terms of office. Our board of directors is authorized to appoint persons to the offices set forth in our amended and r","filed_date":"2023-04-03","accession":"0001104659-23-040842","full_text":"https://origin.rootz.global/static/filing/0001104659-23-040842.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"COCH","company":"Envoy Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"ai_adoption","strength":40,"match_count":5,"context":"hened balance sheet by extinguishing $32 million in debt* * * *Subsequent to year-end, closed on transformational capital raise led by established institutional healthcare investors and completed enrollment of Pivotal Clinical Trial for first-of-its-kind fully implanted cochlear implant* ** ** **White Bear Lake, Minnesota March 23, 2026** Envoy Medical Inc. (NASDAQ: COCH) (Envoy Medical or the Compan","filed_date":"2026-03-27","accession":"0001213900-26-035483","full_text":"https://origin.rootz.global/static/filing/0001213900-26-035483.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"COCH","company":"Envoy Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"ai_adoption","strength":40,"match_count":5,"context":"from extended warranty plans is recognized ratably over time and was immaterial for each of the three and nine months ended September 30, 2024 and 2023. Amounts received from a customer prior to fulfillment of the performance obligation are included in accrued expenses on the condensed consolidated balance sheets and are immaterial as of September30, 2024 and December 31, 2023. The Company has electe","filed_date":"2024-11-14","accession":"0001213900-24-097861","full_text":"https://origin.rootz.global/static/filing/0001213900-24-097861.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"COCH","company":"Envoy Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"ai_adoption","strength":40,"match_count":5,"context":"venue from extended warranty plans is recognized ratably over time and was immaterial for each of the three and six months ended June 30, 2024 and 2023. Amounts received from a customer prior to fulfillment of the performance obligation are included in accrued expenses on the condensed consolidated balance sheets and are immaterial as of June 30, 2024 and December 31, 2023. The Company has elected to","filed_date":"2024-08-12","accession":"0001213900-24-067381","full_text":"https://origin.rootz.global/static/filing/0001213900-24-067381.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"COCH","company":"Envoy Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"ai_adoption","strength":40,"match_count":5,"context":"sis. Revenue from extended warranty plans is recognized ratably over time and was immaterial for each of the three months ended March 31, 2024 and 2023. Amounts received from a customer prior to fulfillment of the performance obligation are included as accrued expenses on the condensed consolidated balance sheets and are immaterial as of March 31, 2024 and December 31, 2023. The Company has elected t","filed_date":"2024-05-15","accession":"0001213900-24-043566","full_text":"https://origin.rootz.global/static/filing/0001213900-24-043566.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"COCH","company":"Envoy Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"ai_adoption","strength":40,"match_count":5,"context":"e Company also sells extended warranty plans on a limited basis. Revenue from extended warranty plans is recognized ratably over time and is immaterial. Amounts received from a customer prior to fulfillment of the performance obligation are included as accrued expenses on the condensed consolidated balance sheets and are immaterial as of September 30, 2023 and December 31, 2022. The Company has elect","filed_date":"2024-01-17","accession":"0001213900-24-004149","full_text":"https://origin.rootz.global/static/filing/0001213900-24-004149.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"COCH","company":"Envoy Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":40,"match_count":5,"context":"ridge Note. When calculating the fair value of the Convertible Notes as of June 30, 2023, Envoy used an incorrect input in the valuation model related to the Convertible Notes settlement value upon a Merger with a Special Purpose Acquisition Company (SPAC). Specifically, the Business Combination Agreement includes the assumed exchange ratio of Envoy common stock, par value $0.01 per share (Envoy Common Stock","filed_date":"2024-01-17","accession":"0001213900-24-004149","full_text":"https://origin.rootz.global/static/filing/0001213900-24-004149.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"COCH","company":"Envoy Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"ai_adoption","strength":40,"match_count":5,"context":"e Company also sells extended warranty plans on a limited basis. Revenue from extended warranty plans is recognized ratably over time and is immaterial. Amounts received from a customer prior to fulfillment of the performance obligation are included as accrued expenses on the condensed consolidated balance sheets and are immaterial as of September 30, 2023 and December 31, 2022. The Company has elect","filed_date":"2023-11-17","accession":"0001213900-23-088310","full_text":"https://origin.rootz.global/static/filing/0001213900-23-088310.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"COCH","company":"Envoy Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":40,"match_count":5,"context":"ridge Note. When calculating the fair value of the Convertible Notes as of June 30, 2023, Envoy used an incorrect input in the valuation model related to the Convertible Notes settlement value upon a Merger with a Special Purpose Acquisition Company (SPAC). Specifically, the Business Combination Agreement includes the assumed exchange ratio of Envoy common stock, par value $0.01 per share (Envoy Common Stock","filed_date":"2023-11-17","accession":"0001213900-23-088310","full_text":"https://origin.rootz.global/static/filing/0001213900-23-088310.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"COCH","company":"Envoy Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":39,"match_count":3,"context":"may be required to reduce certain of its discretionary spending. The Company may be unable to develop new or enhanced production methods, or be unable to fund capital expenditures, which could have a material adverse effect on the Companys financial position, results of operations, cash flows, and ability to achieve its intended business objectives. These matters raise substantial doubt about the Companys ability to con","filed_date":"2024-11-14","accession":"0001213900-24-097861","full_text":"https://origin.rootz.global/static/filing/0001213900-24-097861.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"COCH","company":"Envoy Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":39,"match_count":3,"context":"may be required to reduce certain of its discretionary spending. The Company may be unable to develop new or enhanced production methods, or be unable to fund capital expenditures, which could have a material adverse effect on the Companys financial position, results of operations, cash flows, and ability to achieve its intended business objectives. These matters raise substantial doubt about the Companys ability to con","filed_date":"2024-08-12","accession":"0001213900-24-067381","full_text":"https://origin.rootz.global/static/filing/0001213900-24-067381.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"COCH","company":"Envoy Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":39,"match_count":3,"context":"may be required to reduce certain of its discretionary spending. The Company may be unable to develop new or enhanced production methods, or be unable to fund capital expenditures, which could have a material adverse effect on the Companys financial position, results of operations, cash flows, and ability to achieve its intended business objectives. These matters raise substantial doubt about the Companys ability to con","filed_date":"2024-05-15","accession":"0001213900-24-043566","full_text":"https://origin.rootz.global/static/filing/0001213900-24-043566.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"COCH","company":"Envoy Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"margin_pressure","strength":32,"match_count":4,"context":"e, any of which could limit the amounts that federal, state, and foreign governments will pay for healthcare products and services, which could result in reduced demand for our products or additional pricing pressure. **** **Anti-Bribery and Corruption Laws** Our U.S.operations are subject to the Foreign Corrupt Practices Act (*FCPA*).We are required to comply with the FCPA, which generally prohibits covered enti","filed_date":"2026-03-23","accession":"0001213900-26-032683","full_text":"https://origin.rootz.global/static/filing/0001213900-26-032683.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"COCH","company":"Envoy Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"margin_pressure","strength":32,"match_count":4,"context":"anizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our products. We expect to experience pricing pressures in connection with the sale of any of our product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative chang","filed_date":"2025-12-18","accession":"0001213900-25-123367","full_text":"https://origin.rootz.global/static/filing/0001213900-25-123367.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"4459766c2133d4603e827c978af46fb9d64ac1279da0b04288a0041d2eba24f1","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"cded64c884d245cdea70d7996bb15e6cfaa29d8c66bacd12a3cd4aad8991d032","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256() || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":104,"hourly_limit":500,"remaining":396,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}